EUVIMEDEUVIMED entdecken
Crossref

Physiologically based pharmacokinetic (PBPK) modeling of gliclazide for different genotypes of CYP2C9 and CYP2C19

Hye-Jung Park, Sang-Ho Lee, Pureum Kang, Chang-Keun Cho, Choon-Gon Jang, Seok-Yong Lee, Yun Jeong Lee, Jung-Woo Bae, Chang-Ik Choi

Archives of Pharmacal Research · 2025

DOI: 10.1007/s12272-024-01528-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Pharmacal Research, 2025. Verfasst von Hye-Jung Park und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea. Hauptthemen laut MEDLINE: Gliclazide, Cytochrome P-450 CYP2C9, Cytochrome P-450 CYP2C19, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 82 Literaturangaben. Gefördert von: Ministry of Science and ICT, South Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gliclazide is a sulfonylurea hypoglycemic agent used to treat type 2 diabetes. Cytochrome P450 (CYP) 2C9 and CYP2C19 are primarily involved in the hepatic metabolism of gliclazide. The two CYP isozymes are highly polymorphic, and their genetic polymorphisms are known to significantly impact the pharmacokinetics of gliclazide. In the present study, the physiologically based pharmacokinetic (PBPK) model was developed using data from subjects whose pharmacokinetic parameters were influenced by the genetic polymorphisms of the CYP metabolic enzymes. All predicted plasma concentration-time profiles generated by the model showed visual agreement with the observed data, and the pharmacokinetic results were within the twofold error range. Individual simulation results showed additional metrics: average fold error (- 0.19 to 0.07), geometric mean fold error (1.13-1.56), and mean relative deviation (1.18-1.58) for AUC, Cmax, T1/2, Tmax, CL/F, and Vd values. These results met the standard evaluation criteria. The validation across a total of 8 studies and 7 races also satisfied the twofold error range for AUC, Cmax, and T1/2. Therefore, variations in gliclazide exposure according to individuals' CYP2C9 and CYP2C19 genotypes were properly captured through PBPK modeling in this study. This PBPK model may allow us to predict the gliclazide pharmacokinetics of patients with genetic polymorphisms in CYP2C9 and CYPC19 under various conditions, ultimately contributing to the realization of individualized drug therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliclazideCytochrome P-450 CYP2C9Cytochrome P-450 CYP2C19Hypoglycemic AgentsModels, BiologicalHumansGenotypePolymorphism, GeneticMaleAdultFemaleMiddle Aged

Stichwörter der Autor:innen

CYP2C19CYP2C9Genetic polymorphismGliclazidePharmacokineticsPhysiologically based pharmacokinetic (PBPK) model

Substanzen

GliclazideCytochrome P-450 CYP2C9Cytochrome P-450 CYP2C19CYP2C9 protein, humanCYP2C19 protein, humanHypoglycemic Agents

Autor:innen und Institutionen

  • School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
  • College of Pharmacy, Dongguk University-Seoul, Goyang, 10326, Republic of Korea.
  • School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea. sylee@skku.edu.
  • College of Pharmacy, Dankook University, Cheonan, 31116, Republic of Korea.
  • College of Pharmacy, Keimyung University, Daegu, 42601, Republic of Korea.
  • College of Pharmacy, Dongguk University-Seoul, Goyang, 10326, Republic of Korea. cichoi@dongguk.edu.

Förderung

  • Ministry of Science and ICT, South Korea

Zitieren

APA

Park, H. J., Lee, S. H., Kang, P., Cho, C. K., Jang, C. G., Lee, S. Y., Lee, Y. J., Bae, J. W., & Choi, C. I. (2025). Physiologically based pharmacokinetic (PBPK) modeling of gliclazide for different genotypes of CYP2C9 and CYP2C19. Archives of Pharmacal Research. https://doi.org/10.1007/s12272-024-01528-8

Vancouver

Park HJ, Lee SH, Kang P, Cho CK, Jang CG, Lee SY, et al. Physiologically based pharmacokinetic (PBPK) modeling of gliclazide for different genotypes of CYP2C9 and CYP2C19. Archives of Pharmacal Research. 2025. doi:10.1007/s12272-024-01528-8

BibTeX
@article{Park2025,
  author = {Park, Hye-Jung and Lee, Sang-Ho and Kang, Pureum and Cho, Chang-Keun and Jang, Choon-Gon and Lee, Seok-Yong and Lee, Yun Jeong and Bae, Jung-Woo and Choi, Chang-Ik},
  title = {Physiologically based pharmacokinetic (PBPK) modeling of gliclazide for different genotypes of CYP2C9 and CYP2C19},
  journal = {Archives of Pharmacal Research},
  year = {2025},
  doi = {10.1007/s12272-024-01528-8}
}
Kostenlos starten →